A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer

NCT05846516 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: VSV-GP154
DRUG: ATP150
DRUG: ATP152
DRUG: Ezabenlimab
DRUG: ATP162

Sponsor

Boehringer Ingelheim